Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Dose, Fixed-Sequence, Two-Period, Two-Treatment Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD-1211 Following an Intravenous Infusion and an Oral Dose of [14C]TD-1211 in Healthy Male Subjects

Next Previous
X
Search
Trial Profile

A Single-Dose, Fixed-Sequence, Two-Period, Two-Treatment Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD-1211 Following an Intravenous Infusion and an Oral Dose of [14C]TD-1211 in Healthy Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axelopran (Primary) ; Axelopran (Primary)
  • Indications Constipation
  • Focus Pharmacokinetics
  • Sponsors Theravance; Theravance Biopharma

    • Most Recent Events

    • 23 May 2014 Status changed from active, no longer recruiting to completed; as reported by ClinicalTrials.gov record.
    • 14 Feb 2013 Planned End Date changed from 1 Jan 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 14 Feb 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top